Please assess the completion status of the following clinical trial:

Trial Title: MRI With C13 Pilot Study Prostate Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The subject has biopsy-proven adenocarcinoma of the prostate with intermediate to high risk disease by UCSF CAPRA scoring and possesses a Gleason 4 component to the tumor. Subjects will be enrolled either prior to radical prostatectomy (N=5) or prior to 2 months of androgen deprivation therapy (LHRH agonist +/- antiandrogen) followed by definitive radiation therapy as their primary treatment for prostate cancer (N=5).~* The subject is able and willing to comply with study procedures and provide signed and dated informed consent.~* At least 5 mm of tumor on biopsy (can have multiple cores to comprise 5 mm).~* The subject has concordant MRI/1H MRSI findings from a MR staging exam at UCSF performed prior to the 13C MRSI exam performed in this study with IMP, or is willing to undergo MRI/1H MRSI in connection with the study exam.~* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.~* Laboratory criteria for protocol entry:~* Absolute neutrophil count (ANC) ≥1000 cells/µL~* Hemoglobin ≥9.0 gm/dL~* Platelets ≥75,000 cells/µL~* Estimated creatinine clearance ≥50 mL/min~* Total bilirubin ≤1.5x ULN (or if ≤4 gm/dL and direct bilirubin is WNL)~* Aspartate aminotransferase (AST) ≤1.5x ULN~* Alanine aminotransferase (ALT) ≤1.5x ULN~* Willing to use contraception during and for 1 month after completion of the study.~* For part 2 of the study: plans to initiate castrating therapy (with a GnRH antagonist, GnRH agonist, or orchiectomy). An antiandrogen may be started after initial imaging but can not be used prior to baseline imaging. An antiandrogen is allowed but not required.~Exclusion Criteria:~* The subject has received, or is scheduled to receive, another IMP from 1 month before to 1 month after inclusion in this study.~* Current or prior androgen deprivation therapy; previous use of a 5-α reductase inhibitor is allowed, provided it was discontinued at least one month prior to study entry.~* Poorly controlled hypertension, with blood pressure at study entry\>160/100.~* Contraindication for or inability to tolerate MRI examination.~* Prostate biopsy within 12 weeks prior to study entry.~* BMI of less than 18.5 or greater than 32. Subject body weight should be less than or equal to 100 kg owing to limitations in the amount of IMP available.~* Congestive heart failure or New York Heart Association (NYHA) status≥2.~* A history of clinically significant EKG abnormalities, including QT prolongation, a family history of prolonged QT interval syndrome, or myocardial infarction (MI) less than 1 year ago with ensuing unstable EKG.~* Ongoing acute or chronic pulmonary bronchospastic disease, including a history of chronic obstructive pulmonary disease or asthma, with an exacerbation within the past year.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1: Reproducibility (Type: EXPERIMENTAL): Pyruvate injection followed by an MRI scan. 2-3 weeks after imaging #1: a second pyruvate injection followed by an MRI scan.
- Part 2: Treatment Response (Type: EXPERIMENTAL): Pyruvate injection followed by an MRI scan. 2 months after imaging #1: a second pyruvate injection followed by an MRI scan.

Based on this trial design, predict the completion outcome and termination type (if applicable).